Vaccination approaches to combat human metapneumovirus lower respiratory tract infections

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Human metapneumovirus (hMPV), identified in 2001, is a significant cause of respiratory infections in children, the elderly, and immunocompromised individuals.
• hMPV infection presents with symptoms ranging from mild upper respiratory illness to severe conditions like bronchiolitis and pneumonia.
• Two distinct, antigenically different hMPV lineages circulate globally, though antibodies targeting the F protein offer cross-protection.

Purpose of the Study:

• To review the immunogenicity and protective efficacy of various hMPV vaccine candidates.
• To summarize findings from preclinical studies in animal models.
• To highlight the current status of hMPV vaccine development.

Main Methods:

• Literature review of studies evaluating hMPV vaccine candidates.
• Analysis of data from animal models (rodents and non-human primates).
• Assessment of different vaccine platforms including live attenuated, virus-vectored, inactivated, and subunit vaccines.

Main Results:

• Vaccine candidates targeting hMPV have demonstrated promising immunogenicity and protective effects in various animal models.
• Antibodies against the hMPV F protein are crucial for protection and show cross-reactivity between lineages.
• Despite positive preclinical results, no hMPV vaccine candidate has advanced to human clinical trials.

Conclusions:

• Multiple vaccine strategies are under investigation for hMPV prevention.
• Preclinical data suggest potential for effective hMPV vaccines, particularly those focusing on the F protein.
• Further research and human trials are necessary to establish the safety and efficacy of hMPV vaccines in at-risk populations.